Disclosures
A.J.C. reports personal fees from AbbVie, Acadia, Alfasigma, Alkermes, Attentive, Corium, Intracellular Therapies, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Neuroscience Education Institute, Noven, Sunovion, Takeda, and Teva; grants from Arbor, Axsome, Biohaven, KemPharm, Novartis, and Purdue; grants and personal fees from Akili Interactive, Axsome, Otsuka, Sage, Supernus, and Tris Pharma; and data safety monitoring board for Cognitive Research, outside the submitted work. K.S., B.S., K.B., M.K., S.M., and M.C. report nonfinancial support during the conduct of the study and personal fees outside the submitted work from Noven Pharmaceuticals, Inc. A.C. reports research funding from Akili Interactive, Allergan, Arbor, Emalex, Ironshore, KemPharm, Lumos, Neos Therapeutics, Otsuka, Pfizer, Purdue, Rhodes, Servier, Sunovion, Supernus, Takeda (Shire), and Tris Pharma; consultancy/advisory role with Aardvark, Adlon, Akili Interactive, Arbor, Aytu, Cingulate, Corium, Ironshore, Jazz, KemPharm, Lumos, Medison Pharma, Neos Therapeutics, Neurocentria, Noven, Otsuka, Pfizer, Purdue, Rhodes, Sky, Sunovion, Supernus, Takeda (Shire), Tris Pharma, and Tulex; speakers' bureau for Arbor, Corium, Ironshore, Neos Therapeutics, Pfizer, Supernus, Takeda (Shire), and Tris Pharma; and nonfinancial support from Arbor, Ironshore, Neos Therapeutics, Noven, Pfizer, Purdue, Rhodes, Sunovion, Takeda (Shire), and Tris Pharma.